Objective The aim of the GENDRIVAX (GENome-DRIVen Vaccine) scientific programme is to develop novel prophylactic vaccines against invasive bacterial diseases caused by Salmonella and Neisseria. GENDRIVAX intends to combine the results of recent industrial research (novel platform technologies for producing highly affordable outer membrane antigen based vaccines for Gram-negative bacteria) with the detailed knowledge of the biology of Salmonella and Neisseria infections in Africa supplied by the academic partners. The aim is to make and test the revolutionary concept of vaccines that will be pan-specific.This project is based on collaboration between four institutes:1. Novartis Vaccines Institute for Global Health S.r.l. (NVGH), the industrial partner with a specific mission to develop vaccines for neglected diseases of developing countries.2. Wellcome Trust Sanger Institute (WTSI), academic institution working in the research areas of genetics.3. Swiss Tropical Institute (STI), a public non-commercial organisation with the mission of contributing to health development.4. Kenya Medical Research Institute (KEMRI), the national body responsible for carrying out health science research in Kenya.The four partners have existing links that form the basis for developing an effective working relationship. However, the academic partners and the industrial partner collaborations are at an early stage (NVGH had its inauguration in February 2008). GENDRIVAX comes at an ideal time as it provides a perfect opportunity to bring together academic innovation with industrial expertise through joint training and exchange initiatives.This activity of Industry-Academia cooperation aims at fulfilling the following goals:1) to harmonise European research programmes, in order to achieve a critical mass on relevant topics;2) to foster exchange of scientists;3) to further improve the quality of European vaccine research of relevance for the developing countries. Fields of science natural sciencesbiological sciencesgeneticsnatural sciencesbiological sciencesmicrobiologybacteriologymedical and health scienceshealth sciencesmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines Programme(s) FP7-PEOPLE - Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Topic(s) FP7-PEOPLE-2009-IAPP - Marie Curie Action: "Industry-Academia Partnerships and Pathways" Call for proposal FP7-PEOPLE-2009-IAPP See other projects for this call Funding Scheme MC-IAPP - Industry-Academia Partnerships and Pathways (IAPP) Coordinator GSK VACCINES INSTITUTE FOR GLOBAL HEALTH SRL Address Via fiorentina 1 53100 Siena Italy See on map Region Centro (IT) Toscana Siena Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Allan Saul (Mr.) Links Contact the organisation Opens in new window Website Opens in new window EU contribution € 748 338,00 Participants (3) Sort alphabetically Sort by EU Contribution Expand all Collapse all GENOME RESEARCH LIMITED United Kingdom EU contribution € 392 084,00 Address The gibbs building, euston road 215 NW1 2BE London See on map Region London Inner London — West Camden and City of London Activity type Research Organisations Administrative Contact Stuart Rayner (Mr.) Links Contact the organisation Opens in new window Website Opens in new window SCHWEIZERISCHES TROPEN UND PUBLIC HEALTH INSTITUT Switzerland EU contribution € 427 226,00 Address Kreuzstrasse 2 4123 Allschwil See on map Region Schweiz/Suisse/Svizzera Nordwestschweiz Basel-Landschaft Activity type Research Organisations Administrative Contact Stefan Moergeli (Prof.) Links Contact the organisation Opens in new window Website Opens in new window KENYA MEDICAL RESEARCH INSTITUTE Kenya EU contribution € 71 990,00 Address Off mbagathi way 00200 Nairobi See on map Activity type Research Organisations Administrative Contact Charles Mwandawiro (Dr.) Links Contact the organisation Opens in new window Website Opens in new window
